Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent MBT Plasma in ICU COVID-19
NCT04547127Phase 2Completed
- Sponsor
- Grifols
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Plasma product, Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of convalescent anti-SARS-CoV-2 MBT plasma in coronavirus disease 2019 (COVID-19), sponsored by Grifols. Started Apr 2020; status: completed.
02
Drugs
convalescent anti-SARS-CoV-2 MBT plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04547127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04547127.